Boundless changes plans for cancer drug after toxicity issues
Boundless Bio has hit the reset button in the face of toxicity issues, nixing ongoing treatment arms in an early-stage cancer study in favor of a new combination for its CHK1 inhibitor. And, in a ...
Boundless Bio has hit the reset button in the face of toxicity issues, nixing ongoing treatment arms in an early-stage cancer study in favor of a new combination for its CHK1 inhibitor.
And, in a ...
